Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:56:13.354Z.
Consensus retrieved: 2026-10-06T11:10:57.405Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:56:13.354Z.
Quote observation: 2026-10-06T15:54:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 86fff216fe9f4e43fb815e843488a8aee31e33e8cf855d0ea3412f6f5fc7b913
Forward PE Ratio (N/A) = Dated Quote Price ($12.25) / Consensus Forward EPS ($-2.20)
FORWARD PE RATIO
N/A
Enanta Pharmaceuticals, Inc.
Market Cap
$356.11M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Enanta Pharmaceuticals, Inc. (ENTA) | $356.11M | N/A |
| Embecta Corp. (EMBC)vs › | $356.26M | 3.41 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $356.41M | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $355.58M | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $358.34M | 36.41 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $352.10M | N/A |
| Ocugen, Inc. (OCGN)vs › | $362.81M | N/A |
| Opus Genetics, Inc. (IRD)vs › | $364.53M | N/A |
| Canopy Growth Corporation (CGC)vs › | $374.62M | N/A |
| Agenus Inc. (AGEN)vs › | $336.87M | 30.24 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-09-30
At the dated quote price of $12.25, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-09-30 | $-2.20 | $-2.34 – $-2.06 | 4 | n/m |
| 2028-09-30 | $-2.67 | $-3.95 – $-1.28 | 4 | n/m |
| 2029-09-30 | $-3.05 | $-3.55 – $-2.55 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
